Stem Cells and Stromal Vascular Fraction for Temporomandibular Joint Disease

TC Erciyes University

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Temporomandibular Joint Pain; Temporomandibular Joint Osteoarthritis; Temporomandibular Joint Disorders; Temporomandibular Disorder; Temporomandibular Joint Effusion

Treatments: Biological: Stem Cells

Study type: Interventional

Funder types: Other

Identifiers

NCT05305833

2021/584

Details and patient eligibility

About

It will be evaluate the safety of mesenchymal stem cells and adipose tissue derived stromal vascular fraction (SVF) in temporomandibular joint disease cases.

Full description

umbilical cord derived mesenchymal stem cells produced under GMP facility in Erciyes University and SVF produced in operation theatre.

Enrollment: 20 estimated patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Chronic temporomandibular arthritic disorder
• History of pain and joint noises for at least 3 months
• Must have more than VAS 5 TMJ pain
• must have internal derangement of TMJ
• Limited mouth opening
• Magnetic resonance imaging evidence of effusion or degeneration
• Already treated with conservative methods (occlusal splint,pharmacological and/or physio-kinesio therapy) without satisfactory benefit.

Exclusion criteria

• Cancer patients
• Immunosupressed patients
• Previous TMJ traumas and fractures
• Previous TMJ surgeries
• TMJ ankylosis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

20 participants in 2 patient groups

umbilical cord derived mesenchymal stem cells transplantation group

Experimental group

Description:

taking umbilical cord derived mesenchymal stem cells

Treatment:

Biological: Stem Cells

stromal vascular fraction cells application group

Experimental group

Description:

taking stromal vascular fraction cells

Treatment:

Biological: Stem Cells